Drug Information Related to Temovate
Back
01. What Kind of Eczema Treatment Can You Expect?
Eczema, a term used by most people to refer to Atopic Dermatitis, is an incurable disease which affects the skin. Although sure is not a possibility, there are things you can do to control the symptoms.
These things are a combination of medical attention and at ho...
02. Taro Pharmaceutical Industries announces FDA approval for clobetasol ....
HAWTHORNE, N.Y.--(BUSINESS WIRE)--July 16, 1996--Taro taro: see arum. Pharmaceutical Industries Ltd. (NASDAQ/NMS:TAROF) Tuesday reported its wholly owned subsidiary, Taro Pharmaceuticals Inc., of Ontario, Canada, has received notification from the U.S. Food ...
03. Research and Markets : Study the Global Consumer Healthcare Activities...
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c19709) has announced the addition of Corporate Focus Healthcare: GlaxoSmithKline Q1 2005 to their offering. Problems continue for GlaxoSmithKline. The company delivered a poor set of...
04. ALPHARMA ANNOUNCES FDA APPR OVAL OF CHLORHEXIDINE GLUCONATE ORAL RINSE...
FORT LEE, N.J.--(BUSINESS WIRE)--January 2, 1996--ALPHARMA INC. (NYSE:ALO ALO - A Live One (Phish album)ALO - Academie Voor Lichamelijke OpvoedingALO - Accounting Liaison OfficeALO - Aegis Light OffALO - Afghanistan Liberation OrganisationALO - Agency Liaison OfficerA...
05. Taro Pharmaceuticals Reports Record Fourth Quarter Results and Record ...
Business Editors HAWTHORNE, N.Y.--(BUSINESS WIRE)--Feb. 24, 2000Key Appointment in Business DevelopmentTaro Establishes UK SubsidiaryHighlights
- Q4 Sales Increase to $22.3 Million, compared with $19.7 Million in Q4 98
- Q4 Net Income Increases to $1.7 Mi...
06. Taro Pharmaceuticals Reports Record Fourth Quarter, Year-End Results ....
Business EditorsHAWTHORNE, N.Y.--(BUSINESS WIRE)--Feb. 22, 2001Taro Pharmaceuticals (Nasdaq/NMS:TARO):Highlights:
-- Q4 2000 Sales Increase 34% to $29.9 Million
-- Q4 2000 Net Income Increases 105% to $3.5 Million, or $0.29 per Diluted
Share, from $1.7 Million,...
07. Chronic plaque psoriasis | American Family Physician | Find Articles a...
Table 1
Topical therapies for Chronic Plaque Psoriasis
Mechanism
Drug class/drug(s) of action Dosage
Topical steroids
Various potent Controls Mometasone: 0.1%
or very potent inflammation ...
08. Topical clobetasol urged for lichen sclerosus tx | OB/GYN News | Find ...
HOUSTON -- Ultrapotent topical clobetasol should be the mainstay of treatment for genital lichen sclerosus, despite a widely held belief that it shouldn't be used on the vulva, according to Dr. Elizabeth Edwards.
...
09. Erosive lichen planus may be in vulva and vagina | OB/GYN News | Find ...
HOUSTON -- If a patient has erosive lichen planus of the vulva, chances are she's got it in the vagina as well, and it's essential to treat it there to prevent scarring that could dose the vagina completely according to Dr. Elizabeth Edwards.
...
10. Pick Estrogen Cream Carefully for Lichen Sclerosus | OB/GYN News | Fin...
BIG SKY, MONT. -- Many patients with refractory lichen sclerosus simply aren't using their medications properly, Dr. Lane J. Mercer said at an ob.gyn. update sponsored by the University of Chicago. But by choosing the most appropriate medications to treat the conditio...
11. Taro's Clobetasol emollient wins approval of its ANDA | Drug Store New...
Taro Pharmaceutical Industries reported that Taro Pharmaceuticals U.S.A., the company's U.S. subsidiary, has received Food and Drug Administration approval of its ANDA for Clobetasol Propionate emollient cream USP, 0.05% ("Clobetasol E Cream"). The product i...
12. Taro Pharmaceuticals Announces FDA Approval; Agency Approves ANDA For ...
Hawthorne, N.Y.--(BUSINESS WIRE)--Nov. 19, 1998--Taro Pharmaceutical Industries Ltd. (Nasdaq/NM:TAROF) Thursday reported that it received notification from the U.S. Food and Drug Administration (FDA) approving its Abbreviated New Drug Application (ANDA) for Clobetasol...
13. Taro's ANDA for Clobetasol Propionate Gel, 0.05% approved | Drug Store...
The Food and Drug Administration has approved Taro Pharmaceutical Industries' ANDA for Clobetasol Propionate Gel, 0.05%. The ANDA was submitted by the company's wholly owned subsidiary, Taro Pharmaceuticals Inc. of Ontario, Canada. Taro's Clobetasol Propionate Gel is ...
14. Medical nutrition therapy as a potential complementary treatment for ....
Introduction
...
15. Short-term safety assessment of clobetasol propionate 0.05% shampoo .....
In conclusion, under the conditions of this study, clobetasol propionate shampoo did not lead to any HPA axis suppression, or to skin atrophy. Conversely, the gel formulation led to HPA axis suppression and to skin thickness decrease. None of the formulations had an i...